Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

Discovery Matters

55. The injustice of disease burden and access to vaccines

26 May 2022

Description

The pandemic has been a global issue, which has benefitted from the coming together of industry, pharma, academia, non-governmental and governmental support. What the pandemic has also brought into sharp focus is the global imbalance access to healthcare and health inequity between the Global North and Global South. For this important conversation, we are joined by Professor Linda-Gail Bekker, Chief Operating Officer of the Desmond Tutu HIV Foundation about the current situation with HIV and TB in Africa, and the impact COVID-19 has had on patients already suffering from communicable diseases. So, what can we do? Lenias Hwenda, founder and CEO of Medicines for Africa, explains the additional problems of access to medicines and potential solutions for global vaccine inequity, working to make medicines as inexpensive as possible, and improving the supply chain. Transcript Related reading – Dzau, V.J., Balatbat, C.A., Offodile II, A.C., Closing the global vaccine equity gap: equitably distributed manufacturing. The Lancet. 2022;399(10339): 1924-1926. DOI: https://doi.org/10.1016/S0140-6736(22)00793-0 The Global Biopharma Resilience Index How localizing manufacturing is helping the Middle East take control of its vaccine supply? Keywords: equitable access, HIV, human immunodeficiency viruses, Lentivirus, medicines, pandemic, countries, vaccine, TB, epidemic, Africa, supply chain, communicable diseases, middle-income countries, access, low-income countries, Global North, Global South, disease burden.

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
šŸ—³ļø Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.